Vaccination boosts protective responses and counters SARS-CoV-2-induced pathogenic memory B cells

Much is to be learned about the interface between immune responses to SARS-CoV-2 infection and vaccination. We monitored immune responses specific to SARS-CoV-2 Spike Receptor-Binding-Domain (RBD) in convalescent individuals for eight months after infection diagnosis and following vaccination. Over time, neutralizing antibody responses, which are predominantly RBD specific, generally decreased, while RBD-specific memory B cells persisted. RBD-specific antibody and B cell responses to vaccination were more vigorous than those elicited by infection in the same subjects or by vaccination in infection-naïve comparators. Notably, the frequencies of double negative B memory cells, which are dysfunctional and potentially pathogenic, increased in the convalescent subjects over time. Unexpectedly, this effect was reversed by vaccination. Our work identifies a novel aspect of immune dysfunction in mild/moderate COVID-19, supports the practice of offering SARS-CoV-2 vaccination regardless of infection history, and provides a potential mechanistic explanation for the vaccination-induced reduction of “Long-COVID” symptoms.

SARS-CoV-2 infection, which had been confirmed in 81/83 subjects by virus-specific PCR [two subjects were diagnosed by their physicians based on household exposure history, symptoms, and chest x-ray findings], induced mild to moderate symptoms in the vast majority of subjects, with only 5 (6%) reporting COVID-19-related hospitalization (demographics and clinical information are found in Supplemental Table 1). Of these 83 subjects, 22 completed between three and six study visits between April and December 2020. The demographics and clinical severity of these 22 subjects did not substantively differ from the overall study population except that this group included no participants who had been hospitalized for COVID-19 (Supplemental Table 2). We first analyzed the plasma samples of all 83 infected subjects for levels of antibodies directed to the receptor binding domain (RBD) of the SARS-CoV-2 Spike protein. The coronavirus Spike protein mediates viral entry into host cells and determines host range and tissue tropism (16). The S1 subunit of this protein interacts with the host receptor through its RBD (17). We chose to measure antibody responses to RBD because it is immunodominant and features poor sequence conservation among coronaviruses (16), which minimizes the potential detection of cross-reactive antibodies. We found that detection of RBD-specific antibodies well separated subjects that had tested positive to SARS-CoV-2 PCR (n = 83) from negative control subjects [pre-COVID-19 (n = 104) and SARS-CoV-2 PCR-negative subjects (n = 103) that remained SARS-CoV-2 PCRnegative for at least 16 weeks after the blood draw tested in the figure] (Fig. 1A). To monitor antibody responses over time, we retained 22 subjects for serial blood draws (monthly for 3 months and then bimonthly) over a period of seven months. We observed that the trajectories of RBD-specific IgG, IgM, and IgA antibodies were heterogeneous ( Fig. 1B-D). In particular, the IgG response declined over time in 16 subjects (73%) while it remained stable or increased in 6 subjects (27%) (Fig. 1B). We also analyzed the virus neutralization activity of the plasma collected at the first and last study visit, using an assay with the natural SARS-CoV-2 virus. Neutralization activity decreased in most subjects (n = 15, 68%) (Fig. 1E) [the method for calculating neutralization titer 50 (NT50) is in Supplemental Fig. 1B]. When we compared neutralization titers (NT50) ( Fig. 1E) with RBD-specific antibody titers (Supplemental Fig. 1A), we observed a positive correlation (r = 0.71; p<0.0001) between neutralizing titers and RBD-specific IgG titers (Fig. 1F), as also seen by others (for example, (18)). However, establishing correlations between RBD-specific IgG levels and plasma neutralizing activity only provides indirect evidence of a link between the two parameters. Moreover, demonstrating that RBD is a target of neutralizing antibodies (19)(20)(21)(22) does not directly address the relative contribution of RBD-specific antibodies to the overall plasma neutralizing activity. To directly test the link between RBD specificity and the antibodymediated ability of plasma to neutralize the virus, we depleted RBD-specific antibodies from seropositive plasma samples, and, as a comparator, we also depleted viral Nucleocapsid (N)-specific antibodies, and then tested the effects on neutralizing activity.
We selected 10 plasma samples with high neutralizing activity and removed the antigen-specific antibodies from the plasma by incubation over multiple rounds with RBD or N (or no antigen) in solid-phase, prior to the neutralization assay. We confirmed that the pre-incubation process with either antigen resulted in depletion of the corresponding specific IgG, as demonstrated by ELISA (Fig. 1G-H). We found that the neutralizing activity of the plasma was abrogated only when the samples were . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 14, 2021. ; https://doi.org/10.1101/2021.04.11.21255153 doi: medRxiv preprint preabsorbed with RBD, but not when they were preabsorbed with N (Fig. 1I). This provides direct evidence that the plasma neutralizing activity resides in the RBD-specific antibodies. Collectively, the data show that, at least in subjects that have experienced mild symptoms, circulating levels of RBD-specific IgG tend to decrease over time, with concurrent reduction of plasma neutralizing power. Decreases in circulating antibody below levels of detection will lead to an underestimation of the prevalence of SARS-CoV-2 infection using serological methods. However, this is likely mitigated by infections occurring in the population over consecutive pandemic waves, resulting in noncontemporaneous antibody trajectories in the overall population at any given time. In addition, our antibody depletion approach (that we find used only in another recent COVID-19 report (23)) directly shows that most (if not all) neutralizing activity of plasma resides in the RBD-specific antibodies. These results connect the protective properties of plasma with the molecular characterization of neutralizing monoclonal antibodies, thus providing a framework for antibody-based therapeutics and the rigorous assessment of the value of plasma therapy of COVID-19, which remains controversial (24).
The progressive decrease of protective antibodies in the circulation raises the question of whether immune protection against SARS-CoV-2 infection also wanes over time. We thus analyzed the memory B cell response in the same subjects. To do so, we developed a multicolor flow cytometry panel to measure frequencies of circulating B cells (CD19 + CD20 + ) and B cell subsets including plasmablasts (CD27 + CD38 hi ), naïve (CD27 -IgD + ), and memory B cell compartments [non-switched memory (CD27 + IgD + ), . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 14, 2021. ; https://doi.org/10.1101/2021.04.11.21255153 doi: medRxiv preprint switched memory (CD27 + IgD -), and double negative memory (CD27 -IgD -)] ( Fig. 2A-E).
We also evaluated frequencies of RBD-specific B cells (RBD-tetramer-positive CD19 + CD20 + ) (Fig. 2F), which we further subdivided into the memory compartments in  Table 3). Analysis of RBD + memory B cells in the first-vs last-visit samples showed stable frequencies over time, indicating a durable memory response (Fig. 2H). Notably, the frequency of an RBD + double negative memory (DNM) B cell subset (CD27 -IgD -) increased between the two study visits (Fig. 2I, left panel). This increase was even stronger for the total pool of DNM B cells (Fig. 2I, right panel). This subset, which increases with age (29), is considered a component of the B cell memory compartment despite the absence of the CD27 memory markers, because it bears signatures of antigen experienced B cells in terms of surface phenotype, proliferation response, and patterns of somatic hypermutations (30,31). DNM B cells likely constitute a heterogeneous B cell subset, as they have been described as exhausted / prematurely senescent B cells in HIV infection and other diseases characterized by chronic immune . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 14, 2021. ; activation (32,33), or as producing autoantibodies in autoimmune diseases such as systemic lupus erythematosus (SLE) (34). Interestingly, SARS-CoV-2-induced exhaustion and senescence phenotypes have been previously reported for T cells (35).
Thus, our data suggest that immune exhaustion, which presumably correlates with the RNA vaccines) in 12 cohort members (i.e., previously infected). As comparators, we also tested 8 non-infected subjects that were SARS-CoV-2 PCR-negative and seronegative prior to vaccination. We found that vaccination induced very vigorous antibody responses in both groups and that the response was much higher in infected than non-infected subjects (Fig. 3A). Moreover, IgG titers were much higher in noninfected vaccinated than infected non-vaccinated subjects at the first study visit (Fig.   3B). We also analyzed the effect of vaccination in the two groups on plasma . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 14, 2021. ; https://doi.org/10.1101/2021.04.11.21255153 doi: medRxiv preprint neutralization titers and RBD-specific memory B cell frequencies. Similar to the effect on antibody response, we found that vaccination induced stronger neutralizing activity in the previously infected group (Fig. 3C). Also, vaccination of the non-infected group led to a stronger neutralizing activity than infection alone (Fig. 3D). We also found that vaccination of the infected group led to higher RBD-specific memory B cell frequencies than vaccination of the non-infected group (Fig. 3E). Collectively, these results demonstrate that administration of COVID-19 RNA vaccines induces vigorous humoral and B cell responses, and a strong recall response in subjects previously exposed to the virus. Moreover, our data suggest that vaccination elicits stronger responses than (at least mild) SARS-CoV-2 infection. Analysis of the memory B cell pool showed that, in both groups, vaccination has no effect on circulating plasmablast frequencies and is associated with remodeling and/or redistribution in the periphery of B cell memory compartments (increased naïve and decreased switched memory B cells) in response to vaccination (Supplemental Table 4). Interestingly, the frequencies of doublenegative memory B cells decreases in previously infected individuals (but not in noninfected subjects) following vaccination (Fig. 3F). These declines were statistically significant despite the small sample size. Thus, our results strongly suggest that the response to vaccine counters the infection-induced increased production of potentially dysfunctional and pathogenic immune cells (Fig. 2I). This effect requires confirmation from larger studies.

Conclusions.
In subjects who have experienced mild SARS-CoV-2 infection, we show that the decrease of circulating protective antibodies over time is accompanied by durable memory responses that are competent to induce potent recall responses upon . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 14, 2021. ; https://doi.org/10.1101/2021.04.11.21255153 doi: medRxiv preprint re-exposure to antigen. Our works confirms studies showing potent immune responses induced by anti-SARS-CoV-2 vaccines (for example, (15,40)). In particular, we show that the humoral and B cell response to vaccination is more vigorous than that induced

Acknowledgements. We thank the PHRI biosafety officers and RBHS Institutional
Biosafety committee for fast-track review and approval of laboratory protocols and practices related to handling of SARS-CoV-2 and infected biospecimens; Daniel Fine and Steven Libutti for supporting the start of our COVID-19 work; Nancy Reilly and the . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) and Life Science Editors for professional editorial services. This work was funded by NIH grants R01 HL149450, R01 HL149450-S1, U01 AI122285-S1, and UL1 TR003017.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Plasma was heat-inactivated at 56°C for 1 hour prior to use. After blocking, diluted plasma was added in blocking buffer and incubated for 1 hour at 37°C. Antigen-specific IgG was detected by adding alkaline phosphatase-conjugated goat anti-human IgG (Jackson ImmunoResearch, West Grove PA). ELISA plates were developed using phosphate substrate (Sigma-Aldrich) and the reaction was stopped with 1M NaOH. The ELISA protocol was performed using a BioTek EL406 combination washer dispenser, and absorbance (OD405nm) was measured using a BioTek Synergy Neo2 microplate reader (BioTek, Winooski VT). Each ELISA plate contained positive and negative serum/plasma controls and background control wells without primary antibody. Each sample was tested in duplicate. End-point titers were plotted for each sample using background-subtracted data. All work involving blood products from SARS-CoV-2infected subjects were performed in a biosafety level 2+ (BSL-2+) laboratory utilizing protocols approved by the Rutgers Institutional Biosafety Committee.

Expression and purification of Recombinant SARS-COV-2 S1 RBD Protein
A DNA fragment encoding RBD (Spike residues aa. 319 to aa. 537) was amplified and cloned into the eukaryotic expression vector pcDNA3.1 (Addgene, Watertown MA).
Purified plasmid was transfected into 293F cells using the Expi293 Expression system . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Supernatants were collected on day 3 post-transfection, purified by HisPur TM Cobalt
Resin (Thermo Fisher Scientific) and eluted with 200mM imidazole. Purified protein was subsequently dialyzed against PBS at 4°C. Absorbance (OD280nm) was determined by Nanodrop reading and concentrations were calculated using ExPASy Proteomics calculator. Molecular weights were adjusted to account for the number of N-linked glycosylation sites to determine the final concentration.

Absorption of convalescent plasma with SARS-CoV-2 antigens
ELISA 96-well microtiter plates were coated with 500 ng/well of SARS-CoV-2 RBD or N proteins at 4°C overnight. Coated plates were washed three times with washing buffer and blocked with PBS containing 1% BSA (Sigma-Aldrich) for 30 min at 37°C. After washing, plasma samples were diluted 1:10 in PBS containing 1% BSA (Sigma-Aldrich) and incubated up to overnight at 4°C for each cycle. Absorption was repeated at least four times utilizing fresh antigen-coated plates at each cycle. To monitor depletion of antigen-specific antibodies, RBD-and N-specific IgG titers of untreated and absorbed samples were determined as described above, prior to use in neutralization assays.

Cell lines
Vero E6 were obtained from the American Type Culture Collection (ATCC; Manassas VA) and HeLa cells stably expressing ACE2 (HeLa-ACE2) were obtained from Dennis Burton at the Scripps Research Institute (21). All cell lines were maintained in highglucose Dulbecco's modified Eagle's medium (DMEM; Corning, Manassas VA) . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

SARS-CoV-2 neutralization assay
HeLa-Ace2 cells were seeded in 96-well black optical-bottom plates at a density of 1 × 10 4 cells/well in FluoroBrite DMEM (Thermo Fisher Scientific) containing 4% FBS (Seradigm), 2mM L-glutamine (Corning),1% penicillin/streptomycin (Corning) and incubated overnight at 37°C with 5% CO2. On the following day, each sample was subjected to two-fold serial dilution in DMEM without FBS, and incubated with mNG SARS-CoV-2 at 37°C for 1.5 h. The virus-plasma mixture was transferred to

96-well plates containing Hela-Ace2 cells at a final multiplicity of infection (MOI)
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 14, 2021. ; https://doi.org/10.1101/2021.04.11.21255153 doi: medRxiv preprint of 0.25 (viral PFU:cell). For each sample, the starting dilution was 1:20 and the final dilution of 1:10,240. After incubating infected cells at 37°C for 20 h, mNG SARS-CoV-2 fluorescence was measured using a Cytation TM 5 reader (BioTek). Relative fluorescent units were converted to percent neutralization by normalizing the sample-treatment to non-sample-treatment controls and plotted with a nonlinear regression curve fit to determine the titer neutralizing 50% of SARS-CoV-2 fluorescence (NT50). Each patient sample was tested in duplicate. All plasma samples were heat-inactivated at 56°C for 60 min before testing.

PBMC isolation and storage
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll density gradient centrifugation (Ficoll-Paque, GE Healthcare, Uppsala, Sweden), as described (46). Briefly, whole blood was diluted with equal volume of Roswell Park Memorial Institute Medium (RPMI; Corning) and layered on Ficoll-Paque (GE healthcare, USA).
The gradient was centrifuged at 500 × g for 30 min at room temperature. Plasma was carefully removed, aliquoted, and stored at −80°C. The PBMC interface was collected, washed once, and counted using a hemocytometer. PBMCs were cryopreserved in liquid nitrogen in FBS containing 10% dimethyl sulfoxide (DMSO; Thermo Fischer Scientific) and stored until use.
(Thermo Fischer Scientific) at 4:1 molar ratio for 1 hour at 4°C to form the RBD tetramer . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Correlation analysis was performed using the non-parametric Spearman's rank correlation. Statistical analysis was performed utilizing either Mann-Whitney U test for unpaired samples or Wilcoxon matched pairs signed rank test for paired samples. With all tests, p < 0.05 was considered significant.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.   is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

RBD + MBC DNM
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in pe (which was not certified by peer review) The copyright holder for th this version posted April 14, 2021. ; https://doi.org/10.1101/2021.04.11.21255153 doi: medRxiv preprint